Immunotherapy plus chemoradiation for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 years old.
- You have cervical cancer caused by HPV (squamous cell, adenocarcinoma, or adenosquamous type).
- Your cancer is locally advanced (stage 3A to 4A) or has spread to nearby lymph nodes, but not to distant organs.
- You have not had prior treatment with immune checkpoint inhibitors or other cancer immunotherapy.
- You have not used high-dose steroids or immune-suppressing drugs in the last 2 weeks.
- You are able to receive brachytherapy (internal radiation) as part of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called enlansibumab (an immunotherapy that helps your immune system fight cancer) given with standard chemotherapy and radiation for locally advanced cervical cancer. It aims to see if adding this drug improves outcomes for patients whose cancer has spread to nearby lymph nodes but not to distant organs.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Hear when a new LOCALLY ADVANCED CERVICAL CANCERS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.